Lucid Diagnostics (LUCD) Projected to Post Earnings on Monday

Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) is expected to be announcing its earnings results before the market opens on Monday, March 24th. Analysts expect Lucid Diagnostics to post earnings of ($0.15) per share and revenue of $1.42 million for the quarter. Persons that are interested in participating in the company's earnings conference call can do so using this link.

Lucid Diagnostics Trading Up 3.0 %

Shares of LUCD stock traded up $0.05 during trading hours on Thursday, hitting $1.55. The company's stock had a trading volume of 1,109,397 shares, compared to its average volume of 348,370. The business has a fifty day moving average of $1.17 and a 200-day moving average of $0.97. The stock has a market cap of $91.68 million, a price-to-earnings ratio of -1.35 and a beta of 1.34. Lucid Diagnostics has a twelve month low of $0.63 and a twelve month high of $1.63.

Wall Street Analyst Weigh In

Separately, Ascendiant Capital Markets cut their target price on shares of Lucid Diagnostics from $7.25 to $7.00 and set a "buy" rating on the stock in a research note on Monday, December 9th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $3.63.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.